Caffeine Protects Against Disruptions of the Blood-Brain Barrier in Animal Models of Alzheimer's and Parkinson's Diseases
Open accessThe DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Abstract
Sporadic Alzheimer's disease (AD) and Parkinson's disease (PD) are two of the most common neurodegenerative diseases and as such they represent major public health problems. Finding effective treatments for AD and PD represents an unmet and elusive goal largely because these diseases are chronic and progressive, and have a complicated and ill-understood pathogenesis. Although the underlying mechanisms are not fully understood, caffeine, the most commonly ingested psychoactive drug in the world, has been shown in human and animal studies to be protective against AD and PD. One mechanism implicated in the pathogenesis of AD and PD is blood-brain barrier (BBB) dysfunction and we reported recently that caffeine exerts protective effects against AD and PD at least in part by keeping the BBB intact. The present review focuses on the role of BBB dysfunction in the pathogenesis of AD and PD, caffeine's protective effects against AD and PD, and potential mechanisms whereby caffeine protects against BBB leakage.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Astrocyte-endothelial interactions at the blood-brain barrier
Abbott, N. J., Rönnbäck, L., & Hansson, E. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1824 · Cited by 5,595
Alzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420
Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397
Vassar, R., Bennett, B. D., Babu-Khan, S., Kahn, S., Mendiaz, E. A., Denis, P., Teplow, D. B., Ross, S., Amarante, P., Loeloff, R., et al. (1999) · Science · doi:10.1126/science.286.5440.735 · Cited by 3,876
The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders
Zlokovic, B. V. (2008) · Neuron · doi:10.1016/j.neuron.2008.01.003 · Cited by 3,280 · cited 2×
“As mentioned earlier, the BBB limits the entry of blood-borne pathogens, substances, drugs, and cells into brain parenchyma and helps regulate and protect the microenvironment of the brain such that once the BBB is disrupted, synaptic and neuronal functions are compromised [5].”
BackgroundBlennow, K., de Leon, M. J., & Zetterberg, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69113-7 · Cited by 3,134
The blood-brain barrier/neurovascular unit in health and disease
Hawkins, B. T., & Davis, T. P. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.2.4 · Cited by 2,661
FINE STRUCTURAL LOCALIZATION OF A BLOOD-BRAIN BARRIER TO EXOGENOUS PEROXIDASE
Reese, T. S., & Karnovsky, M. J. (1967) · The Journal of Cell Biology · doi:10.1083/jcb.34.1.207 · Cited by 2,629 · cited 1×
“system separate from the systemic circulation [1–3] and”
BackgroundFredholm, B. B., Bättig, K., Holmén, J., Nehlig, A., & Zvartau, E. E. (1999) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01396-6 · Cited by 2,624 · cited 6×
“At higher concentrations, caffeine and its intermediate metabolites such as theophylline, theobromine, and paraxanthine can elevate intracellular cAMP levels by inhibiting cAMP PDE activity [137].”
BackgroundInfluentialOccludin: a novel integral membrane protein localizing at tight junctions.
Furuse, M., Hirase, T., Itoh, M., Nagafuchi, A., Yonemura, S., Tsukita, S., & Tsukita, S. (1993) · The Journal of cell biology · doi:10.1083/jcb.123.6.1777 · Cited by 2,580 · cited 1×
“One of the first transmembrane tight junction proteins described is occludin, a 65 kDa phosphoprotein [7,8].”
Background
Cited by
Caffeine: Cognitive and Physical Performance Enhancer or Psychoactive Drug?
Cappelletti, S., Daria, P., Sani, G., & Aromatario, M. (2015) · Current Neuropharmacology · doi:10.2174/1570159x13666141210215655 · Cited by 631
“…this finding deserves further investigation in broader population samples (recreational and professional athletes, untrained individuals) and occasions (during exercise or recovery), caffeine in addition to post-exercise carbohydrates consumption seems to be able to stimulate glycogen resynthesis.”
BackgroundFrom purines to purinergic signalling: molecular functions and human diseases
Huang, Z., Xie, N., Illes, P., Di Virgilio, F., Ulrich, H., Semyanov, A., Verkhratsky, A., Sperlagh, B., Yu, S.-G., Huang, C., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00553-z · Cited by 489
How does adenosine control neuronal dysfunction and neurodegeneration?
Cunha, R. A. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13724 · Cited by 441
Solfrizzi, V., Custodero, C., Lozupone, M., Imbimbo, B. P., Valiani, V., Agosti, P., Schilardi, A., D’Introno, A., La Montagna, M., Calvani, M., et al. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-170248 · Cited by 352
Duarte, J. M. N., Agostinho, P. M., Carvalho, R. A., & Cunha, R. A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0021899 · Cited by 130
Metadata
- Authors
- Chen, X., Ghribi, O., & Geiger, J. D.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2010-04-14
- Volume
- 20
- Issue
- s1
- Pages
- S127-S141
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W1620810572
- Cited by
- 132
- References
- 57
- FWCI
- 3.75
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Caffeine Protects Against Disruptions of the Blood-Brain Barrier in Animal Models of Alzheimer's and Parkinson's Diseases. https://app.cochat.ai/papers/10.3233/jad-2010-1376
- The paper
- Chen, X., Ghribi, O., & Geiger, J. D. (2010). Caffeine Protects Against Disruptions of the Blood-Brain Barrier in Animal Models of Alzheimer's and Parkinson's Diseases. Journal of Alzheimer's Disease. https://doi.org/10.3233/jad-2010-1376
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.